Noticias

El Foro Social y Empresarial celebra un encuentro sobre salud e investigación como oportunidad para el desarrollo empresarial

Author
Navarrabiomed
  • La reunión, organizada por el Consejo Social de la UPNA, ha tenido lugar en la sede de Navarrabiomed

El Foro Social y Empresarial del Consejo Social de la Universidad Pública de Navarra (UPNA) ha celebrado esta mañana una reunión sobre “La medicina personalizada y la investigación y servicios en Salud como oportunidad para el desarrollo empresarial de Navarra”. El encuentro, presidido por el vicerrector de Investigación de la UPNA, Patxi Arregui, y el presidente del Consejo Social, Javier Vidorreta, ha tenido lugar en la sede de Navarrabiomed, centro mixto de investigación biomédica de Gobierno de Navarra y de la UPNA.

La reunión ha comenzado a las 12:00 horas con una breve intervención del presidente del Consejo Social, Javier Vidorreta, quien ha señalado que una de las principales funciones del citado consejo es “ayudar a conectar a la universidad con el entorno y eso se traduce en muchas acciones, como este Foro Social y Empresarial, una serie de encuentros y jornadas con los que brindamos la oportunidad de conectar a nuestros docentes e investigadores con los agentes más relevantes del tejido social y empresarial de nuestra comunidad”.

En concreto, ha recordado que esta jornada parte de una actividad anterior organizada por el Consejo Social en la que se trabajó sobre las oportunidades detectadas por las empresas en el campo de la medicina personalizada. “En esta ocasión ampliamos el campo de actuación y debatiremos sobre las diferentes oportunidades empresariales que puede encontrar Navarra en investigación e innovación tecnológica en diferentes ámbitos de la salud. Se trata de un tema alineado con uno de los sectores clave para Navarra recogido en la S3 y con los objetivos del plan estratégico de la UPNA en diferentes ámbitos de la formación y de la investigación, en campos como la medicina, ingeniería, ciencia de datos, biomedicina, fisioterapia, entre otros”.

A continuación y tras el saludo de Iñigo Lasa, director de Navarrabiomed, la sesión se ha centrado en la mesa redonda “Medicina personalizada, innovación en Salud y sector empresarial: la oportunidad de la cercanía”, en la que han intervenido Juan Cruz Cigudosa, consejero de Universidad, Innovación y Transformación Digital del Gobierno de Navarra; Ángel Alonso, responsable del programa NAGEN; y Carlos Artundo, director general de Salud.

En su intervención, el consejero ha puesto de manifiesto que Navarra se encuentra a la cabeza en esta materia, ya que es una de las capitales de la genómica a nivel estatal, y ha subrayado que será la primera región que contará con una Estrategia Integral de Medicina Personalizada de precisión a largo plazo, que incluye más de 50 acciones y cuyo objetivo final es “implementar esta nueva medicina que tiene en el centro, más que nunca, al paciente y su individualidad”.

En cuanto a sus expectativas sobre la colaboración público privada, Cigudosa ha afirmado que, por un lado, puede dar lugar a la generación de empresas con base tecnológica y, por otro lado, “las necesidades de este tipo de medicina también harán posible que empresas dedicadas, por ejemplo, a la digitalización se acerquen a Navarra buscando una oportunidad de negocio en colaboración con los centros que participan en la estrategia. Se trata de un sistema que se retroalimenta y que conforma a Navarra como un importante destino de innovación en salud”, ha añadido.

Posteriormente ha tenido lugar un debate abierto a todos los asistentes, y el presidente del Consejo Social, Javier Vidorreta, ha resumido y puesto en común las conclusiones de la jornada. Esta ha concluido a las 14:00 horas con unas palabras de despedida por parte del vicerrector Patxi Arregui y del consejero Juan Cruz Cigudosa.

El Foro Social y Empresarial

El Foro Social y Empresarial del Consejo Social de la UPNA promueve la participación y el asesoramiento social al citado consejo y en sus sesiones participan representantes del Consejo Social, del equipo rectoral, de la Fundación Universidad-Sociedad y profesionales relevantes del entorno de la universidad.

Desde su creación en 2010, este foro ha servido para debatir y proponer fórmulas sobre el modo de aproximar la UPNA a las necesidades de la sociedad, para introducir innovaciones en los métodos formativos, para fortalecer el empleo de los doctores en el mundo empresarial o para promover la presencia de las mujeres en el ámbito de las ciencias y la tecnología.

Categoría
Galería de imágenes
El Foro Social y Empresarial se celebró en el salón de actos de Navarrabiomed.
Download Flecha que indica descarga
Documentación

Professionals from CHN, Navarrabiomed and AIN to participate in HEALCIER, pioneering cross-border circular economy project

Author
Navarrabiomed

 

  •     The initiative was awarded €613,666 in European funding through the Working Community of the Pyrenees. 
     

The cross-border HEALCIER Project, which aims to improve the competitiveness of the healthcare industry by applying circular economy criteria, with the participation of the Association of Industry of Navarra (AIN), the Hospital Complex of Navarre and Navarrabiomed–Miguel Servet Foundation, was recently selected to receive funding through the Working Community of the Pyrenees (CTP) in the most recent call for projects. The project seeks to generate opportunities for companies and encourage the emergence of new economic activities that make more efficient and effective use of resources.

This project was submitted to the third call for projects of POCTEFA (Program for Regional Cooperation Spain-France-Andorra) and approved by its Programming Committee in October 2019. The Government of Navarre participated through the Directorate-General for Foreign Affairs. Nineteen projects were approved and the projects that had received lower scores were placed on a reserve list, as no funds were available for them at that time.

The cross-border POCTEFA 2014-2020 Program, which is managed by the CTP, announced that other projectson the list would be approved every six months, if possible, when funds were made available by the European Regional Development Fund (ERDF). On April 15, the decision was made to approve two more projects on the list, one of which was the HEALCIER Project. 

Participating entities

Navarre will be represented in the project by the AIN and the CHN. Specifically, the CHN’s Economic Management Division will lead the hospital’s participation in the different project actions, and management will be handled by Navarrabiomed-Miguel Servet Foundation. Other public and private entities will also participate in the project, such as the Azaro Foundation, leader of the proposal, and the Biocruces Health Research Institute, both of which are located in Bizkaia. Another participating entity, ESTIA Institute of Technology, is located across the border in Bidart, New Aquitaine.

The meeting of the Programming Committee was one of the last chances for projects to be approved that were on the reserve list of the third call, given that the POCTEFA 2014-2020 Program is about to end. 

The Directorate-General for Foreign Affairs is actively participating in the preparation of the upcoming POCTEFA 2021-2027 Program for Regional Cooperation, which is expected to be drawn up and approved by the European Commission by the end of the year. The first call for projects of the POCTEFA 2021-2027 Program could be launched in 2022.

The project is co-funded (65%) by the European Regional Development Fund (ERDF) through the Interreg Program V-A Spain-France-Andorra (POCTEFA 2014-2020). The goal of the POCTEFA Program is to strengthen the economic and social integration of the Spain-France-Andorra cross-border area. Its help is focused on developing cross-border economic, social and environmental projects through joint strategies in favor of sustainable regional development.
 

Categoría
Documentación

La investigadora del Instituto Cajal Laura López-Mascaraque ofrece una conferencia divulgativa sobre el sentido del olfato en el marco del proyecto INNOLFACT

Author
Navarrabiomed
  • La pérdida del olfato puede ser una señal temprana de enfermedades como el Alzheimer o Parkinson , además de síntoma frecuente de la COVID-19

La doctora en Neurociencias e Investigadora Científica del Consejo Superior de Investigaciones Científicas  (CSIC) en el Instituto Cajal Laura López-Mascaraque impartió el pasado jueves, 4 de marzo, la conferencia online “El poder del olfato: emociones, memoria y enfermedades” actividad divulgativa organizada por Navarrabiomed en el marco del proyecto INNOLFACT . Durante la  sesión expuso la estrecha relación de este sentido con el sistema cognitivo del ser humano y explicó que su pérdida es una señal temprana de enfermedades como Alzheimer y Parkinson entre otras, además de un síntoma característico de la COVID-19.

En el evento López-Mascaraque aportó a los cerca de cien asistentes datos que corroboran la conexión entre personas con enfermedades neurodegenerativas y desajustes del sentido olfativo : “Una pérdida del olfato diagnosticada hace 10 años puede predecir la enfermedad del párkinson, por ejemplo, porque se ha visto que el 96% de pacientes diagnosticados con esa enfermedad tienen problemas olfativos”. Ocurre lo mismo con el Alzheimer, ya que existen distorsiones tempranas: “La corteza olfativa es una de las primeras regiones que se ven afectadas”, aseguró López Mascaraque.

Asimismo, incidió en la anosmia o pérdida completa del olfato causada en pacientes afectados por COVID-19. Según detalló la ponente, las células de soporte de las neuronas olfativas contienen receptores a los que se adhiere con facilidad el virus SARS-CoV-2, lo que produce “una ruptura total de la arquitectura del epitelio olfativo”. 
Por otro lado, en palabras de López-Mascaraque, el sentido olfativo es el más sensible de todos: “Los recuerdos que nos evoca son más fuertes”. Tiene las únicas neuronas del cerebro expuestas al exterior, con su sistema de receptores al que se dedica una parte sustancial del genoma humano. Estas neuronas interpretan las sensaciones olfativas en su camino desde la nariz hasta el cerebro, siendo la ruta más corta a las emociones, evocando recuerdos y tiempos pasados. Un estudio realizado en la Universidad de Rockeffeler demostró que mientras recordamos un 5% de lo que vemos o el 15% de lo que saboreamos, con el olfato somos capaces de evocar un 35%.

El proyecto INNOLFACT

INNOLFACT  es una investigación liderada por la Unidad de Neuroproteómica Clínica de Navarrabiomed bajo la dirección de su Investigador Principal Enrique Santamaría. Al  comienzo del evento, Santamaría realizó una breve introducción de la iniciativa INNOLFACT que tiene como objetivo principal innovar en los diagnósticos mediante la asociación entre el sistema olfativo y las funciones cognitivas. El proyecto está financiado por el Departamento de Desarrollo Económico y Empresarial del Gobierno de Navarra dentro de la convocatoria de proyectos estratégicos de I+D para el periodo 2020 – 2022.

Forman parte del consorcio profesionales de las siguientes entidades: Unidad de Geriatría de Navarrabiomed, Complejo Hospitalario de Navarra (CHN), ADItech Corporación Tecnológica, Centro de Investigación Médica Aplicada (CIMA), Clínica Universidad de Navarra y los laboratorios Ojer Pharma.

Acceso al webinar completo 
 

Categoría
Documentación
Vídeo
El poder del olfato: emociones, memoria y enfermedades

Hospital Complex of Navarre and Navarrabiomed create registry of patients with persistent COVID-19

Author
Navarrabiomed

•    The SNS-O has also created a technical group to set up and coordinate comprehensive care pathways for these patients.

The Navarre Health Service (SNS-O) has created a technical work group to coordinate comprehensive care pathways for patients with persistent COVID-19 (long COVID-19) and post-COVID complications.

This multidisciplinary group is made up of primary care and specialized care professionals from the three geographic areas of the SNS-O and is led by the Service for the Effectiveness and Continuity of Care. Its goals include channeling care to these patients, establishing uniform response pathways and providing tools for treatment and self-care for early functional recovery of patients suffering from after-effects and/or persistent symptoms.

These actions will complement the care provided since May 2020 at the specific post-COVID Pulmonology consultation room for the most severe COVID-19 cases, in conjunction with Nutrition and Rehabilitation, among other medical specialties.

The World Health Organization (WHO) estimates that around 1 in 10 people suffer from long COVID-19 up to 12 weeks after the acute phase of infection. According to the Ministry of Health, the most common symptoms include tiredness, shortness of breath, muscle pain, loss of sense of smell or taste, persistent fatigue, headache and so-called “brain fog,” which describes several symptoms associated with cognitive impairment, such as memory loss, disorientation, and learning and concentration problems.

Furthermore, the less frequent permanent after-effects of COVID-19 include pulmonary fibrosis and long-term or permanent neurological damage.

PersiCOV-19 research project

Navarrabiomed has promoted more than 30 research studies on COVID-19 patients to date. Now, in 2021, the Hospital Complex of Navarre (CHN) and Navarrabiomed have started up the PersiCOV-19 Project, a study that aims to create a registry of patients with persistent COVID-19 in order to compile information, acquire greater knowledge of the disease caused by SARS-CoV-2 and make progress on the research study.

Patricia Fanlo Mateo, a specialist in Internal Medicine, is responsible for the registry and will coordinate the research projects that use it. Other researchers collaborating on this study include Dr. Julio Oteiza Olaso and Dr. Julio Sánchez Álvarez, from the Internal Medicine Service, and Dr. Marina Sesma Arrondo, a primary care specialist at the Barañain Healthcare Center.

The Navarrabiomed Clinical Trials Platform is responsible for design and implementation of the registry. The study was approved by the Ethics Committee for Drug Research of the Community of Navarre (CEIm).

Social support for patients with persistent COVID-19

The study will be implemented with funding from Navarrabiomed, as well as funding from other sources. Specifically, Murieta City Hall raised €655.40 in the Murieta New Year’s Eve Charity Run, an online event that promoted doing exercise as a way of supporting and raising awareness about people suffering from the after-effects of persistent COVID-19.

Yurema Lana González, the Mayor of Murieta, and Javier Martínez de Morentin Urrutia, a Murieta town councilor, recently visited Pamplona to deliver the amount raised by the charity race to Patricia Fanlo Mateo, a specialist in Internal Medicine at the CHN, and Eva Zalba Garayoa, the Head of the Management Area of the Clinical Trials Platform at Navarrabiomed, the organization that will channel the funds through the Miguel Servet Foundation.

In June 2020, the platform of patients with persistent COVID-19 in Navarre was created under the coordination of Virginia Mateo Solana.

Those interested in joining this platform can make contact at this email address: covidpersistentenavarra@hotmail.com.
 

Categoría
Documentación

Constituido el Consorcio del Polo de Innovación Digital de Navarra IRIS integrado por 33 entidades públicas y privadas

Author
Navarrabiomed
  • El Gobierno de Navarra presidirá el Consorcio, en el que se han integrado centros tecnológicos, universidades, clústeres, colegios profesionales y asociaciones empresariales para promover la transformación digital de empresas y Administración

Un total de 33 entidades públicas y privadas integrarán el Consorcio del Polo de Innovación Digital de Navarra-IRIS, que busca mejorar la competitividad de pymes, industria y administraciones públicas a través de la transformación digital. El consejero de Desarrollo Económico y Empresarial, Mikel Irujo, presidirá la comisión rectora del Consorcio de la que también es miembro el consejero de Universidad, Innovación y Transformación Digital, Juan Cruz Cigudosa.

En el día de hoy, se ha constituido el Consorcio del Polo de Innovación Digital de Navarra-IRIS cuyo plenario se ha reunido por primera vez. Además del Gobierno de Navarra, forman parte del consorcio los principales representantes de los sectores industrial, de conocimiento e investigación y tecnológico de la Comunidad Foral, junto con otras administraciones públicas e instituciones. Así, forman parte de ella el Ayuntamiento de Pamplona, las tres universidades (UPNA, UNAV y UNED), los centros tecnológicos NAITEC (de movilidad y mecatrónica de Navarra), Lurederra y ADITech;  la Asociación de la Industria Navarra (AIN); CENER (Centro Nacional de Energías Renovables), CNTA (Centro Nacional de Tecnología y Seguridad Alimentaria); el CSIC a través de IdAB - Instituto de Agrobiotecnología; Navarra Biomed; la Fundación para la Investigación Médica Aplicada (FIMA); y las sociedades públicas INTIA, SODENA  CEIN, así como las empresas tecnológicas Nasertic, Animsa, Tracasa y Tracasa Instrumental.

A ellos se han unido, además, los clústeres NagriFood (de industria agroalimentaria), Enercluster (de energía), ACAN (de automoción), CLAVNA (de la industria audiovisual), ATANA (de tecnologías), el Functional Print Cluster (de impresión funcional); además de la agrupación Desarrollo Sakana-Dinabide, la Cámara de Comercio y la Confederación Empresarial de Navarra (CEN) y. Asimismo, forman parte del Consorcio IRIS el Colegio Oficial de Ingenieros Industriales de Navarra (COIINA), el Colegio de Graduados en Ingeniería Ramas Industriales e Ingenieros Técnicos Industriales de Navarra (CITI) y el Colegio Oficial de Ingenieros de Telecomunicación (COIT).

El hecho de que IRIS haya sido capaz de reunir a los principales actores de la Comunidad Foral ha sido destacado por el Gobierno de Navarra, quien lo ha calificado de “algo único”. Todas las entidades e instituciones trabajarán ahora de forma conjunta y en red para potenciar la digitalización en las pequeñas y medianas empresas y en las propias administraciones públicas, de forma que redunden en una mayor competitividad de la industria y del tejido empresarial, una mejora de los servicios a los ciudadanos y del bienestar de la sociedad.

Intercambio de conocimiento

El trabajo conjunto de todos estos agentes tiene como objetivo fundamental apoyar la transformación digital de la actividad económica de Navarra, por lo que su actividad  se traducirá en la transferencia del conocimiento en materia de I+D, inteligencia artificial, supercomputación, ciberseguridad y robótica, que beneficiará preferentemente a las empresas de Navarra. El Consorcio colaborará con otras iniciativas regionales europeas que tienen los mismos objetivos, prestando servicios a empresas y facilitando su acceso a instalaciones de experimentación que se encuentren situadas en dichas regiones.     

Las entidades participantes en IRIS se comprometen a prestar diversos servicios al Consorcio y a colaborar con el resto de integrantes del Consorcio. Entre las funciones fundamentales de IRIS están la atracción de talento y la formación; la transferencia de conocimiento; la experimentación y la consultoría; el fomento del emprendimiento y la divulgación.

Para su funcionamiento en el día a día, el Consorcio se estructura en una comisión rectora, presidida por el consejero Mikel Irujo e integrada por el Ayuntamiento de Pamplona, la UPNA, la Universidad de Navarra, NAITEC, AIN, Nasertic, Animsa, ADITech, Sodena, CEIN y Tracasa. Además, se ha constituido un plenario, en el que están presentes los 33 socios. Por último, desde ADITech realizarán las labores de coordinación.

El Consorcio se ha establecido como una agrupación sin personalidad jurídica para concurrir a la convocatoria de Polos Europeos de Innovación Digital de la Comisión Europea. Este Consorcio es un paso previo, en modalidad multi-sede y virtual, a la creación del Polo de Innovación Digital de Navarra, que se ubicará en el terreno anexo a la UPNA.  El Consorcio, cuya gobernanza se ha formalizado hoy, está abierto a la incorporación tanto de entidades colaboradoras, públicas y privadas, como de nuevos socios.

La información sobre las actividades del Polo de Innovación Digital se puede encontrar en el sitio www.irisnavarra.com.

Categoría

CHN and Navarrabiomed present, in Navarre, the European OPTIMAGE network to optimize drug therapy in the elderly

Author
Navarrabiomed
  • The online event was held yesterday with the participation of more than 150 professionals from hospital, community, social health and research settings

The Navarrabiomed Biomedical Research Center, together with the Hospital Complex of Navarre (CHN), organized an online presentation yesterday to introduce the European OPTIMAGE network in Navarre. OPTIMAGE is being developed within the framework of the Interreg Program V-A Spain-France-Andorra (POCTEFA 2014-2020) under the leadership of the University Hospital Center of Toulouse. More than 150 people from hospital, community and social health settings participated in the event, as well as research and business professionals, not to mention representatives from patients’ associations and members of the public.
 
The goal of OPTIMAGE is to optimize drug therapy in the elderly (an age bracket in which polypharmacy can be common, with some patients taking 10 or 12 different drugs) to avoid adverse effects that can lead to extended hospital stays and worsening of the patient’s prognosis. This situation is technically known as drug iatrogenesis. The project’s aim is to prevent this phenomenon through better cooperation among healthcare professionals on using drugs appropriately. Pharmacists are therefore key members of the multidisciplinary team, which also includes healthcare professionals working to prevent drug iatrogenesis.

Leading the initiative is Nicolás Martínez Velilla, Head of the Navarrabiomed Geriatrics Research Unit and also Head of the CHN Geriatrics Service, who highlighted the network’s multicenter structure. “With OPTIMAGE, we want to join the forces of all agents at the Navarre Health Service by implementing pharmacological optimization, providing instruction, encouraging professionals to take part in internships in different regions in the Pyrenees, and sharing and standardizing protocols and good practices,” Martínez said.
 
Besides Nicolás Martínez, the following people spoke at the presentation: Marisol Fragoso Roanes, Managing Director of Navarrabiomed, Alfredo Martínez Larrea, Managing Director of the CHN, Antonio López Andrés, Assistant Director of Pharmacy and Care at the Navarre Health Service (SNS-O), and Maite Sarobe Carricas, Head of the CHN Pharmacy Service. They all showed their support for this network project, which calls for close management and coordination between the services and units involved.

Maite Sarobe said that OPTIMAGE would considerably improve patient care. She went on to say, “This project gives us the chance to improve care by means of specific polypharmacy screening at the Geriatrics Service, where the goal is to optimize therapeutics among the elderly.” She also stressed the importance of monitoring and supervising drug therapy in the elderly, detecting any interactions, confirming the suitability of the drug and its optimal dose in each case, and understanding that the patient’s suffering may be due to the drug prescribed, as well as the suitability of the drug to the patient’s lifestyle, caregivers and setting.

Other participants at the presentation were Daniel Villanueva Canabal and Victoria Roncal Belzunce, Navarrabiomed project manager and project coordinator, respectively; Ramón San Miguel Elcano, specialist in hospital pharmacy at the CHN; Javier Garjón Parra, Head of the Drug Advisory and Information Service at the SNS-O; and Cecilia Calvo Pita and Goizane Ros Bernaola, specialists in hospital pharmacy at the SNS-O.

Strategic axes

The OPTIMAGE network was created as part of the APTITUDE network for the prevention of dependence in the elderly. OPTIMAGE aims to bolster and complement APTITUDE by including community and hospital pharmacists. Consortium members besides Navarrabiomed include the University Hospital Center of Toulouse (project leader), the Health and Aging Foundation of the Universitat Autònoma de Barcelona and the Andorran Health Service.
The project will operate for 29 months along three main axes: the creation of a network against drug iatrogenesis made up of professionals, patients and family members; the training of different social groups; and the implementation of actions for the elderly to improve drug management, and helping develop the European gerontology excellence center begun by APTITUDE.

Cooperation between professionals is a key means of preventing drug iatrogenesis. The exchange of knowledge across the Pyrenees will therefore help provide a clearer view of the strengths and weaknesses of each territory in the areas of the optimization of drug therapy in geriatrics, the prevention of drug iatrogenesis, therapeutic education, teaching and innovation.

The project is co-funded (65%) by the European Regional Development Fund (ERDF) through the Interreg Program V-A Spain-France-Andorra (POCTEFA 2014-2020). The goal of the POCTEFA program is to strengthen the economic and social integration of the Spain-France-Andorra cross-border area. Its help is focused on developing cross-border economic, social and environmental projects through joint strategies in favor of sustainable regional development.
 

Categoría
Galería de imágenes
Left to right: Nicolás Martínez, Alfredo Martínez, Marisol Fragoso, Antonio López, Maite Sarobe, Daniel Villanueva and Victoria Roncal.
Download Flecha que indica descarga
OPTIMAGE event.
Download Flecha que indica descarga
Vídeo
Evento de lanzamiento del proyecto europeo OPTIMAGE en Navarra
Nicolás
Martínez Velilla
Investigador principal

Navarrabiomed-UPNA researchers Mikel Izquierdo, Humberto Bustince, Miguel Beruete and Iñigo Lasa among top 2% of most frequently cited scientists worldwide

Author
Navarrabiomed
  • This ranking takes into consideration scientific production and the number of times a scientist’s research has been cited, among other factors

A study from Stanford University (USA) includes fifteen researchers from the Universidad Pública de Navarra (UPNA) on its list of the top 2% of active scientists, who number almost 7 million. The ranking, published in the journal PLOS Biology, uses the information in the Scopus database to evaluate scientists based on the impact of their citations.

The Stanford University study includes two rankings: one reflecting the position of researchers based on the impact of their citations throughout their research career (until the end of 2019) and one for the impact of citations in 2019 alone. The first ranking, which covers a scientist’s entire career, includes 15 UPNA researchers. The second, covering only activity in 2019, features a total of 25 UPNA researchers.

The fifteen UPNA scholars and their knowledge areas are as follows, in alphabetical order: Francisco Javier Arregui San Martín (Electronic Technology), Miguel Beruete Díaz (Signal Theory and Communications), Humberto Bustince Sola (Computer Science and Artificial Intelligence), Alfonso Carlosena García (Signal Theory and Communications), Federico J. Castillo Martínez (Ecology), Ignacio Del Villar Fernández (Electronic Technology), Francisco Falcone Lanas (Signal Theory and Communications), Andoni Gil Bravo, (Chemical Engineering), Mikel Izquierdo Redín (Physiotherapy), Iñigo Lasa Uzcudun, (Microbiology), Alayn Loayssa Lasa (Electronic Technology), Manuel López-Amo Sainz (Electronic Technology), Antonio López Martín (Signal Theory and Communications), Carmelo Luis Pérez (Manufacturing Process Engineering), and Pablo Sanchis Gúrpide (Electrical Engineering).

The ranking for 2019 activity features 12 more UPNA researchers, in addition to those listed above: José Antonio Aguilera Andonaga (Applied Physics), Carlos Aragón Garbizu (Applied Physics), Juan Antonio Blanco Vaca (Ecology), Roberto Ezcurra Orayen (Applied Economics), Mikel Galar Idoate (Computer Science and Artificial Intelligence), Antonio García-Hermoso (Physical Education), Iñigo Liberal Olleta (Signal Theory and Communications), Jesús López Taberna (Electrical Engineering), Luis Marroyo Palomo (Electrical Engineering), Asier Marzo Pérez (Computer Languages and IT Systems), Robinson Ramírez Velez (Physiotherapy), and Alfredo Ursua Rubio (Electrical Engineering).

Categoría

Virologist and Navarrabiomed researcher David Escors receives innovation award at 5th SER Radio Network Awards in Navarre

Author
Navarrabiomed

David Escors Murugarren, the principal investigator and head of the Navarrabiomed Oncoimmunology Research Unit and an expert on coronavirus, was the winner at the annual SER Radio Network Awards in Navarre of the innovation award, which is sponsored by the company Viscofan. The jury applauded his research work on SARS-CoV-2, given that he leads a project whose mission is to create a platform for speeding up vaccine production in cases of pandemics like the current COVID-19 pandemic.

In his acceptance speech, Escors highlighted the value of the work done at research centers on a daily basis. “Our lab works every day in the fight against cancer and also against autoimmune diseases, which should not be overlooked, even though we’re now in an emergency situation,” he said. He expressed his gratitude, but also his surprise at winning the award and said, “There are many other scientists working every day, just like us. It’s our work, our passion, and it’s what we studied for and trained to do.” He ended his speech by thanking his family and friends for their support throughout his professional career.

The ceremony of the fifth edition of the SER Radio Network Awards in Navarre was held at the Baluarte Auditorium and hosted by journalist Joaquim Torrents. This year, COVID-19 and its consequences were particularly relevant and the jury naturally took them into account when deciding on the award winners. In total, 10 people or groups were recognized for their work in different facets of Navarre society.
 

Categoría
Vídeo
Premios SER Navarra

UPNA and Navarrabiomed researchers confirm negative effects of lockdown on preschoolers aged 4 to 6

Author
Navarrabiomed
  • In the recently published study, researchers look at the impact on sleep quality, levels of physical activity, sedentary behavior and self-regulation.

The study “Physical activity, sedentary behavior, sleep quality and self-regulation in Spanish preschoolers,” carried out by researchers from the Universidad Pública de Navarra (UPNA) and Navarrabiomed, confirmed that “the impact of home lockdown as a result of COVID-19 has led to increased antisocial behavior, anxiety and even depression-related behavior among preschool children (ages 4-6).” These results are associated with a significant reduction in physical activity, an increase in sedentary behavior and a drop in sleep quality.

This work, published in the International Journal of Environmental Research and Public Health, featured the participation, in March-April 2020, of 268 preschoolers between ages 4 and 6, along with their parents, from three schools in Pamplona. Levels of physical activity and sleep quality were obtained directly using an accelerometer that the participants wore on their wrists for six days.

According to the authors, “Our findings provide evidence of the negative effects of lockdown on physical activity, sedentary behavior, sleep quality and self-regulation.” Specifically, daily physical activity decreased by 43.3 minutes, sedentary behavior increased by 50.2 minutes, and sleep quality fell by 2.09%. The lockdown period also negatively increased anti-social behavior, anxiety and depression-related behavior. The study therefore demonstrates that preschoolers showed increased problems with internalization and externalization during lockdown. “In these age groups, behavioral and emotional problems can potentially trigger problems of internalization (i.e., anti-social behavior) or externalization (i.e., anxiety- or depression-related behavior).” Preschoolers who met WHO minimum recommendations for physical activity during lockdown (180 minutes per day, of which 60 minutes should be of moderate or vigorous intensity) displayed less antisocial behavior.

Limitations encountered

According to the authors, this study is the first to examine the effects of COVID-19 home lockdown on levels of physical activity and sleep in preschool children carried out directly and objectively using accelerometers instead of surveys and personal interviews. In any event, they also pointed out some limitations when analyzing their results. Firstly, it is possible that behavioral changes occurred during the first week of lockdown, when the greatest changes to daily routines took place and families were still adapting to the new situation. “Given that lockdown lasted for several weeks, preschool children may have subsequently reverted back to their normal habits, including their sleep patterns and physical activity.” Secondly, the study faced two major limitations: only a reduced number of children could be measured using accelerometers and there was little time for monitoring. Finally, it cannot be overlooked that children's lifestyles largely depend on the decisions of their parents, and the geographic/urban environment may also have affected the physical activity and sleep patterns of these children.

The authors of the article are Alicia M. Alonso-Martínez, Robinson Ramírez-Vélez, Yesenia García-Alonso, Mikel Izquierdo (Researchers from the Physical Exercise, Health and Quality of Life (E-FIT) Group at the UPNA and Navarrabiomed), and Antonio García-Hermoso (principal investigator and Head of the Physical Activity, Children and Youth Unit at Navarrabiomed). The study falls within the framework of the work of the Physical Activity Observatory for minors between ages 3 and 6 in the Autonomous Community of Navarre. This observatory is a research project financed by the Government of Navarre’s Ministry of Education. Observatory participants include researchers from the Physical Exercise, Health and Quality of Life (E-FIT) Group at the Universidad Pública de Navarra and the Navarrabiomed Biomedical Research Center.
 

Categoría

INNOLFACT aims to assess olfactory function among the elderly and develop new nasal immunomodulator therapies to stop the progress of neurodegenerative disorders

Author
Navarrabiomed
  • The Government of Navarre is funding the project to the tune of €1.7 million.

INNOLFACT is a multicenter initiative whose aim is to implement precision olfactory medicine and develop gender-based nasal immunomodulator therapies, particularly in the areas of aging and neurodegenerative disorders. The Government of Navarre’s Ministry of Economic and Business Development selected ten strategic R&D projects, one of which was INNOLFACT, which earned the highest score of all the candidates and was awarded total funding of €1.4 million for the 2020-2022 period.

A consortium was created to implement the project made up of the institutions involved. The team leader is the Navarrabiomed Clinical Neuroproteomics Unit under the direction of Enrique Santamaría Martínez, the principal investigator (PI) and unit head. The other consortium members include professionals from the Navarrabiomed Geriatrics Unit, the Hospital Complex of Navarre (CHN), ADItech, the Center for Applied Medical Research (CIMA), Clínica Universidad de Navarra and Ojer Pharma laboratories.

Research development

During the research phase, the institutions will focus on the characterization of the olfactory molecular mechanisms involved in the development of neurodegenerative disorders such as Alzheimer’s and Parkinson’s disease, and on jointly assessing the olfactory and immune systems in the aging process. Researchers expect the results to provide predictive biomarkers and, as a result, new nasal immunomodulator therapies that allow for intranasal drug administration instead of conventional intravenous therapy.

Enrique Santamaría, PI and head of the Clinical Neuroproteomics Unit, explained the project’s ambitious goals: “With INNOLFACT, we want to perform an in-depth characterization of the olfactory system-immune system-brain axis. The technological resources made available by consortium members will enable us to carry out an exhaustive molecular characterization of this axis in both humans and animal disease models, which will help us identify and characterize molecules with immunomodulating potential that can also be used for intranasal administration. This provides advantages when treating cerebral disorders that currently have no treatment.”

The consortium will also analyze the olfactory capacity of elderly people with the aim of determining if loss of smell may be a symptom of a weaker immune system and one that is therefore less able to fight neurodegenerative disorders. Work will also be done to offer self-diagnostic tests and specific training sessions designed to improve or stop olfactory deterioration and help strengthen the immune system.

Collaborating institutions

The INNOLFACT research project forms part of the scientific activity of the Navarre Health Research Institute (IdiSNA) with the support and collaboration of different institutions: the Spanish Olfactory Network (ROE), Association of Family Members of Alzheimer’s Patients in Navarre (AFAN), Navarre Association of Parkinson’s Patients (ANAPAR), Spanish Parkinson’s Disease Federation (FEP), Committee of Representatives of Disabled Persons in Navarre (CERMIN) and Federation of People with Physical and Organ-Related Disabilities (COCEMFE NAVARRA). Navarrabiomed also liaises with the Global Consortium for Chemosensory Research (GCCR), where more than 600 researchers from 50 countries participate.

Categoría
Documentación
Vídeo